title: Myoclonus during prolonged treatment with sertraline in an adolescent patient.
abstract: A 15-year-old female adolescent with depression developed myoclonus after uninterrupted treatment with sertraline over 6 years. She was also receiving methylphenidate. Withdrawal of sertraline and continuation of methylphenidate did not result in any improvement. Treatment with valproic acid resulted in improvement of the movement disorder. This report suggests that myoclonus may be a side effect of sertraline in some adolescents. Further, we hypothesized that extended treatment over several years, young age, and a compromised central nervous system due to underlying disorders may be risk factors for the development of this side effect.
authors: Division of Child and Adolescent Psychiatry, University of Michigan, Ann Arbor 48109-0390, USA. neerag@umich.edu
authors: N
authors: N
authors: Ghaziuddin
authors: A
authors: A
authors: Iqbal
authors: S
authors: S
authors: Khetarpal
mesh_terms: D000293:Adolescent; D000927:Anticonvulsants / Q000627:therapeutic use; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects* / Q000627:therapeutic use; D001289:Attention Deficit Disorder with Hyperactivity / Q000188:drug therapy / Q000523:psychology; D000697:Central Nervous System Stimulants / Q000009:adverse effects / Q000627:therapeutic use; D002648:Child; D002659:Child Development Disorders, Pervasive / Q000523:psychology; D002998:Clonazepam / Q000627:therapeutic use; D005260:Female; D006801:Humans; D008774:Methylphenidate / Q000009:adverse effects / Q000627:therapeutic use; D009207:Myoclonus / Q000139:chemically induced* / Q000188:drug therapy / Q000473:pathology; D011559:Pseudotumor Cerebri / Q000150:complications; D012307:Risk Factors; D020280:Sertraline / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D000927:Anticonvulsants; D018687:Antidepressive Agents, Second-Generation; D000697:Central Nervous System Stimulants; D008774:Methylphenidate; D002998:Clonazepam; D020280:Sertraline